Short Interest Change: Cytrx Corporation (NASDAQ:CYTR)’s Trend Unknown, Especially After Increased Shorts

December 1, 2016 - By Winifred Garcia   ·   0 Comments

Short Interest Change: Cytrx Corporation (NASDAQ:CYTR)’s Trend Unknown, Especially After Increased Shorts

The stock of Cytrx Corporation (NASDAQ:CYTR) registered an increase of 7.55% in short interest. CYTR’s total short interest was 9.91 million shares in December as published by FINRA. Its up 7.55% from 9.21 million shares, reported previously. With 685,700 shares average volume, it will take short sellers 14 days to cover their CYTR’s short positions. The short interest to Cytrx Corporation’s float is 15.3%. The stock decreased 12.11% or $0.069 during the last trading session, hitting $0.501. CytRx Corporation (NASDAQ:CYTR) has declined 85.07% since April 28, 2016 and is downtrending. It has underperformed by 91.00% the S&P500.

CytRx Corporation is a biopharmaceutical research and development firm specializing in oncology. The company has a market cap of $49.59 million. The Firm is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It currently has negative earnings. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma whose tumors have progressed after treatment with chemotherapy.

Insitutional Activity: The institutional sentiment increased to 1.85 in 2016 Q2. Its up 0.58, from 1.27 in 2016Q1. The ratio increased, as 10 funds sold all CytRx Corporation shares owned while 16 reduced positions. 10 funds bought stakes while 23 increased positions. They now own 18.94 million shares or 1.05% less from 19.14 million shares in 2016Q1.
Blackrock Ltd last reported 32,619 shares in the company. Miracle Mile Limited Com has 14,286 shares for 0% of their US portfolio. Wells Fargo And Mn holds 34,243 shares or 0% of its portfolio. Principal Grp Incorporated Incorporated reported 11,197 shares or 0% of all its holdings. Price T Rowe Assocs Md, a Maryland-based fund reported 49,900 shares. Blackrock holds 0% of its portfolio in CytRx Corporation (NASDAQ:CYTR) for 6,872 shares. Clear Harbor Asset Mgmt Ltd Liability Com holds 0.01% of its portfolio in CytRx Corporation (NASDAQ:CYTR) for 13,000 shares. Tower Rech Capital Limited Liability (Trc), a New York-based fund reported 3,119 shares. Qvt L P reported 5.42M shares or 0.83% of all its holdings. Highbridge Cap Ltd Liability Com, a New York-based fund reported 89,275 shares. Geode Cap Lc has invested 0% of its portfolio in CytRx Corporation (NASDAQ:CYTR). Citigroup Inc accumulated 0% or 6,729 shares. Camarda Fin Advisors Ltd Com holds 0% of its portfolio in CytRx Corporation (NASDAQ:CYTR) for 758 shares. Grt Capital Prtn Limited Liability Corp last reported 0.02% of its portfolio in the stock. Northern Tru holds 681,599 shares or 0% of its portfolio.

CYTR Company Profile

CytRx Corporation, incorporated on February 28, 1985, is a biopharmaceutical research and development firm specializing in oncology. The Firm is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. The Firm is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. The Firm is also involved in evaluating aldoxorubicin in a global Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus (HIV)-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. The Firm has also completed a global Phase IIb clinical trial with aldoxorubicin as a first-line therapy for STS; a Phase Ib/II clinical trial primarily in the same indication; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors.

More news for CytRx Corporation (NASDAQ:CYTR) were recently published by: Prnewswire.com, which released: “CytRx Corporation Announces Pricing of $20 Million Public Offering of Common …” on July 15, 2016. Prnewswire.com‘s article titled: “CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer” and published on January 11, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>